<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vorinostat (suberoylanilide <z:chebi fb="0" ids="24650">hydroxamic acid</z:chebi>, SAHA) is a <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor active clinically in cutaneous T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and preclinically in <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or thrice daily for 14 days followed by 1-week rest </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with relapsed or refractory <z:hpo ids='HP_0001909'>leukemias</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and untreated patients who were not candidates for chemotherapy were eligible </plain></SENT>
<SENT sid="3" pm="."><plain>Of 41 patients, 31 had <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 4 <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, 3 MDS, 2 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, and 1 <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The maximum tolerated dose (MTD) was 200 mg twice daily or 250 mg thrice daily </plain></SENT>
<SENT sid="5" pm="."><plain>Dose-limiting toxicities were <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Common drug-related adverse experiences were <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:mp ids='MP_0002899'>fatigue</z:mp>, and <z:hpo ids='HP_0002039'>anorexia</z:hpo> and were mild/moderate in severity </plain></SENT>
<SENT sid="7" pm="."><plain>Grade 3/4 drug-related adverse experiences included <z:mp ids='MP_0002899'>fatigue</z:mp> (27%), <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (12%), and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (10%) </plain></SENT>
<SENT sid="8" pm="."><plain>There were no drug-related <z:hpo ids='HP_0011420'>deaths</z:hpo>; 7 patients had hematologic improvement response, including 2 complete responses and 2 complete responses with incomplete blood count recovery (<z:hpo ids='HP_0000001'>all</z:hpo> with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated at/below MTD) </plain></SENT>
<SENT sid="9" pm="."><plain>Increased <z:chebi fb="0" ids="15358">histone</z:chebi> acetylation was observed at <z:hpo ids='HP_0000001'>all</z:hpo> doses </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="11" ids="22586">Antioxidant</z:chebi> gene expression may confer vorinostat resistance </plain></SENT>
<SENT sid="11" pm="."><plain>Further evaluation of vorinostat in <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> is warranted </plain></SENT>
</text></document>